((自动化翻译由路透提供，请见免责声明 )) (第1段增加股份，第2-3段增加细节)
路透12月30日 - Sangamo Therapeutics 周一称，在与合作伙伴辉瑞 终止共同开发协议后，该公司将重新获得其A型血友病基因疗法的权利，这使其股价在延长交易中下跌了30.3%。
Sangamo公司表示，辉瑞公司不会继续提交该疗法（giroctocogene fitelparvovec）的潜在批准申请，也不会将其商业化。
该公司补充说，它将探索推进该计划的所有方案，包括寻求新合作伙伴的可能性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.